Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 5, 2005, Pages 2816-2822

  Reginster, J Y ^a   Seeman, E ^b   De Vernejoul, M C ^c   Adami, S ^d   Compston, J ^e   Phenekos, C ^f   Devogelaer, J P ^g   Curiel, M Diaz ^h   Sawicki, A ⁱ   Goemaere, S ^j   Sorensen, O H ^k   Felsenberg, D ^l   Meunier, P J ^m  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c HÔPITAL LARIBOISIÈRE   (France)

^d Centro Ospedaliero Clinicizato di Medicina Riabilitiva e Preventiva di Valeggio   (Italy)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f RED CROSS HOSPITAL   (Greece)

^g UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^h Hospital UniversitarioFundación Jiménez Díaz   (Spain)

ⁱ Warszawskie Centrum Osteoporozy   (Poland)

^j GHENT UNIVERSITY HOSPITAL   (Belgium)

^k HVIDOVRE HOSPITAL   (Denmark)

^l CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^m EDOUARD HERRIOT HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; STRONTIUM RANELATE;

AGED; ARTICLE; BONE DENSITY; CLAVICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; ECZEMA; FEMALE; FEMUR NECK; FRACTURE; FRAGILITY FRACTURE; GASTRITIS; HEADACHE; HIGH RISK POPULATION; HIP; HUMAN; HUMERUS; MAJOR CLINICAL STUDY; NAUSEA; PELVIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RIB; RISK REDUCTION; SACRUM; STATISTICAL ANALYSIS; STERNUM; WRIST;

AGED; AGED, 80 AND OVER; BONE DENSITY; DOUBLE-BLIND METHOD; FEMALE; FRACTURES, BONE; HUMANS; ORGANOMETALLIC COMPOUNDS; OSTEOPOROSIS, POSTMENOPAUSAL; SPINAL FRACTURES; THIOPHENES;

EID: 21044447888     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2004-1774     Document Type: Article

References (24)

1. Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA 1999 Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353:878-882
2. Cummings RS, Melton 3rd LJ 2002 Epidemiology and outcomes of osteoporotic fractures. Lancet 359:1761-1767
3. Youm T, Koval KJ, Kummer FJ, Zuckerman JD 1999 Do all hip fractures result from a fall? Am J Orthop 28:190-194
4. Seeman E 2002 Pathogenesis of bone fragility in women and men. Lancet 359:1841-1850
5. Canalis E, Hott M, Deloffre P, Tsouderos Y, Marie PJ 1996 The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro. Bone 18:517-523
6. Baron R, Tsouderos Y 2002 In vitro effects of S12911-2 on osteoclast function and bone marrow macrophage differentiation. Eur J Pharmacol 450:11-17
7. Takahashi N, Sasaki N, Tsouderos Y, Suda T 2003 S12911-2 inhibits osteoclastic bone resorption in vitro. J Bone Miner Res 18:1082-1087
8. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski J, Spector T, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY 2004 The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459-468
9. Committee for Proprietary Medicinal Products 2001 Note for guidance on post menopausal osteoporosis in women rev. 1
10. Food and Drug Administration 1994 Draft guidance postmenopausal osteoporosis. Preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis
11. Genant HK, Wu CY, van Kuijk C, Nevitt MC 1993 Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137-1148
12. Slosman D, Provvedini DM, Meunier PJ, Delmas PD, Sebert JL, De Vernejoul MC, Tsouderos Y, Reginster JY 1999 The use of different dual x-ray absorptiometry brands in a multicenter clinical trial. J Clin Densitom 2:37-44
13. Donaldson LJ, Cook A, Thomson RG 1990 Incidence of fractures in a geographically defined population. J Epidemiol Community Health 44:241-245
14. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY 2001 Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333-340
15. Chapuy MC, Arlot M, Delmas P, Meunier PJ 1994 Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ 308:1081-1082
16. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. J Am Med Assoc 282:1344-1352
17. Reginster JY, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R 2000 Randomized trial of the effects of risedronate on vertebral fractures in women with established post-menopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83-91
18. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535-1541
19. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. J Am Med Assoc. 280:2077-2082
20. Meunier PJ, Slosman D, Delmas PD, Sebert JL, Brandi ML, Albanese C, Lorenc R, Pors-Nielsen S, De Vernejoul MC, Roces A, Reginster JY 2002 Strontium ranelate: dose-dependent effects in established post menopausal vertebral osteoporosis. The Stratos 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 87:2060-2066
21. Reginster JY, Deroisy R, Dougados M, Jupsin I, Colette J, Roux C 2002 Prevention of early postmenopausal bone loss by strontium ranelate: the randomized, two-year, double-masked, dose-ranging, placebo-controlled PREVOS trial. Osteoporos Int 13:925-931
22. Ammann P, Rizzoli R, Deloffre P, Tsouderos Y, Meyer JM, Bonjour JP 1996 The increase in vertebral bone mass induced in intact rats by long-term administration of the strontium salt S-12911 is directly correlated with vertebral bone strength. Osteoporos Int 6(Suppl 1):259
23. Coulombe J, Faure H, Robin B, Tsouderos Y, Ruat M 2002 Activation of the rat and mouse cation-sensing receptor by strontium ranelate and its modulation by extracellular calcium. Osteoporos Int 13(suppl 1):P70MO
24. Pi M, Quarles LD 2004 A novel cation-sensing mechanism in osteoblasts is a molecular target for strontium. J Bone Miner Res 19:862-869